KRAS and neoplasm: In this study, we found that MitoQ and MitoTEMPO administration had no impact on the number of primary tumors and lymph metastases in mice with BRAF-induced malignant melanoma and no impact on tumor burden in mice with KRAS-induced lung cancer.